MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/95/0.1/20.09.24 | Real-time Bid/Ask 16:19:54 03/06/2024 BST | ||
| 0.046 EUR / 0.048 EUR | +38.24% |
|
| 1 month | +13.33% | ||
| 3 months | +142.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 0.029 | -14.71% |
| 31/05/24 | 0.034 | +25.93% |
| 30/05/24 | 0.027 | -3.57% |
| 29/05/24 | 0.028 | 0.00% |
| 28/05/24 | 0.028 | +12.00% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 11:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME2CJ2 |
| ISIN | DE000ME2CJ23 |
| Date issued | 20/10/2023 |
| Strike | 95 $ |
| Maturity | 20/09/2024 (109 Days) |
| Parity | 10 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.054 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.002 € |
| Spread % | 4.26% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Warrants
- Warrant